These findings suggest that targeting neutrophil serine proteases with brensocatib may offer a new approach for managing bronchiectasis, reducing exacerbation frequency and preserving lung function.

A total of 1,680 adults and 41 adolescents were randomly assigned to brensocatib or placebo. The researchers found that the annualized rate of pulmonary exacerbations was 1.02, 1.04, and 1.29 in ...

Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo ...

Brensocatib significantly reduced the rate of pulmonary exacerbations and slowed lung function decline in patients with non-cystic fibrosis bronchiectasis in the Phase III ASPEN trial. "Bronchiectasis ...

Doctors have known that radiation exposure from computed tomography—also called a CT scan—comes with cancer risk. But the risk seems to be higher than previously expected, according to a new study ...

A mother, her teenage daughter, and her sister who were killed in a crash on Saturday, April 19 in Connecticut will be laid to rest together this weekend. Services for Florinda Antonia Tineo, 50, her ...

Before you leave... As a nonprofit newsroom, we believe the healthiest way to sustain and grow CT Mirror is through the support of people who use and value it — loyal, curious readers like you.

William Stonier, of Ledyard, is charged with failure to maintain a lane, reckless driving, and second-degree manslaughter, Connecticut State Police said. He was previously charged with driving under ...

University housing project in CT city gets $500K boost. Called a ‘a transformative impact.’ “This year’s report highlights the outstanding contributions of our employees and community ...

(WFSB) - Smoke from a large wildfire in New Jersey was forecast to arrive in Connecticut by late Thursday. While the arrival of spring often suggests blooming flowers and gentle breezes, it also ...

The ASPEN study, the largest clinical trial for bronchiectasis to date, has no approved therapies for this chronic lung condition characterized by frequent exacerbations that degrade lung function and ...